Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login



Proposal to involve NICE in approval process for Cancer Drugs Fund

NICE is to be given the reins to the Cancer Drugs Fund

Source: NICE

NHS England proposals will be subject to consultation in September 2015

The evaluation of drugs currently funded under the Cancer Drugs Fund (CDF) could be passed over to National Institute for Health and Care Excellence (NICE) under proposals drawn up by NHS England.

The new proposed model is expected to be more closely aligned with NICE processes. The proposals will be subject to consultation in September 2015, where it is anticipated that the new CDF will be operational from 1 April 2016.

“The emerging proposal is that in future the CDF should become a ‘managed access’ fund for new cancer drugs, with clear entry and exit criteria. It would be used to resource those drugs which appear promising, but where NICE indicates that there is insufficient evidence to support a recommendation for routine commissioning, and where additional evidence would be likely to enable a more informed NICE appraisal decision,” NHS England says.

Instead of a simple failure to recommend, the drug would be given “conditional approval” by NICE and provided through the fund for a defined period, whilst further evidence from “real world” use was collected, it adds.

At the end of this period, the drug would go through an abbreviated NICE appraisal, and then either attract a NICE positive recommendation or a negative one (at which point it would move out of the fund and become available only on the basis of individual patient referral).

The CDF was created in 2010 to pay for drugs that haven’t been approved by NICE, but despite increases from its original budget of £200m per year, its overspending has increased, resulting in the removal of 25 drugs from its list in March 2015 in an effort to save £80m.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069037

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons is the definitive reference source of analytical data for drugs and poisons.

    £535.00Buy now
  • Injectable Drugs Guide

    Injectable Drugs Guide

    A user friendly, single point of reference for healthcare professionals in the safe and effective administration of injectable medicines.

    £54.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.